1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Opportunity Analyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024

Opportunity Analyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024

  • December 2015
  • 237 pages
  • ID: 3716478
In this report:
GLOBALDATA ESTIMATES JAPANESE SALES FOR HCC TO INCREASE FROM $##M IN 2014 TO $##M IN 2024, REPRESENTING A CAGR OF ##%.
UNDER THE LICENSE, NATCO PHARMA IS REQUIRED TO PAY ##% ROYALTY TO BAYER ON THE NET SALES OF THE DRUG ON A QUARTERLY BASIS, ALTHOUGH THIS ROYALTY WILL BE VERY SMALL GIVEN HOW MUCH CHEAPER NATCO'S PRODUCT IS (NATCO, PRESS RELEASE, DECEMBER ##, 2014).

Summary

Table of Contents

Search Inside

Opportunity Analyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024

Brief

Liver cancer is the second leading cause of cancer related death in the globe in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma is the most dominant form of liver cancer, accounting for approximately 85.0 percent of liver cancer cases. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments including surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.

Key Findings

Key questions & answers

- Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and has dominated the HCC market in the seven main markets (7MM: US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)) since its launch.

- The current late and early stage pipeline is very strong and different. Which drug will have the biggest impact on the sector? What strategies are developers undertaking to overcome the high risk of clinical trial failure?

- Nexavar will lose patent protection within the forecast period. How will this impact the HCC market and will additional market entries be able to stabilize the HCC market?

Main highlights

- The principal driver of growth in the HCC market is the expected launch of second-line treatments for patients with advanced HCC. The market increase will be farther supported by an increase in HCC incidence numbers due to an increasing aging population as well as market-specific increase in risk factors.

- The biggest barrier for HCC is the patent expiry of Nexavar and expected introduction of generic sorafenib in the 7MM. The effect of this will be strongest in the US where it will have the most important impact on the HCC market. Farther patent expiries will also have a negative impact on the HCC market.

- The biggest unmet needs in HCC are more treatment options for patients with advanced HCC. First line as well as second line and beyond treatments are urgently needed to improve the treatability of these patients.

Overview

- Overview of HCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized HCC market revenue, annual cost of therapy and treatment usage pattern data from 2014 and estimate for ten years to 2024.

- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the HCC therapeutics market.

- Pipeline analysis: focus on the late-stage pipeline HCC drugs discussing emerging trends as well as overview of earlier phase drugs.

- Analysis of the current and future market competition in the overall HCC therapeutics market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

The market research will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop strategic management by understanding the trends shaping and driving the overall HCC therapeutics market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall HCC therapeutics market in future.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analysing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Track drug sales in the overall HCC therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017

Clinical Research in Liver Failure (Hepatic Insufficiency) in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H2, 2017" ...

Hepatitis A Global Clinical Trials Review, H2, 2017

Clinical Research in Hepatitis A in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Hepatitis A Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hepatitis A Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis A clinical trials ...

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Clinical Research in Hepatocellular Carcinoma in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.